human gdf 15 quantikine enzyme linked immunosorbent assay elisa kit  (R&D Systems)

Journal: The Journal of Nutrition, Health & Aging

Article Title: Association of growth differentiation factor-15 with muscle wasting and anemia in chronic kidney disease

doi: 10.1016/j.jnha.2026.100835

Figure Lengend Snippet: Factors associated with GDF-15. Univariate analysis of the correlations of GDF-15 with the (a) estimated glomerular filtration rate (eGFR), (b) ln urine protein-to-creatinine ratio (UPCR), (c) ln N-terminal pro-B-type natriuretic peptide (NT-proBNP), (d) hemoglobin, (e) ln interleukin-6 (IL-6), (f) ln tumor necrosis factor-α (TNF-α), (g) albumin, and (h) lean tissue index.

Article Snippet: Plasma levels of GDF-15 were quantified using the Human GDF-15 Quantikine enzyme-linked immunosorbent assay (ELISA) Kit (R&D Systems, Minneapolis, MN, USA), with intra- and inter-assay coefficients of variation <5%.

Techniques: Filtration

Journal: The Journal of Nutrition, Health & Aging

Article Title: Association of growth differentiation factor-15 with muscle wasting and anemia in chronic kidney disease

doi: 10.1016/j.jnha.2026.100835

Figure Lengend Snippet: Kaplan–Meier curves by growth differentiation factor-15 (GDF-15) median. Participants with GDF-15 concentrations above the median had a higher cumulative incidence of all-cause mortality than those with lower concentrations (log-rank P < 0.001). Numbers at risk are shown below the plot.

Article Snippet: Plasma levels of GDF-15 were quantified using the Human GDF-15 Quantikine enzyme-linked immunosorbent assay (ELISA) Kit (R&D Systems, Minneapolis, MN, USA), with intra- and inter-assay coefficients of variation <5%.

Techniques:

Journal: Science Advances

Article Title: Inflammatory arthritis irAE may represent a unique autoimmune disease primarily driven by T cells but likely not autoantibodies

doi: 10.1126/sciadv.aea4262

Figure Lengend Snippet: ( A ) Expression of CD27 and IgD on CD19 + B cells. Right: Percentage of IgD + CD27 − naïve B cells and IgD − CD27 − DN B cells. ( B ) Expression of CD27 and CD38 on CD19 + B cells. Right: Percentages of CD27 hi CD38 hi ASCs and CD27 + CD38 − memory B cells. ( C ) Expression of CD138 on CD27 hi CD38 hi ASCs. Right: Percentage of CD138 + ASCs and CD138 − ASCs. ( D ) Expression of CD11c and CD21 on CD19 + B cells. Right: Percentage of CD11c + CD21 − CD19 + B cells. [(A) to (D)] HC ( n = 63), irAE ( n = 33), RAC ( n = 46), and ICI ( n = 20). ( E to G ) GSEA was performed on the B cells between irAE and ICI. (E) Significantly enriched pathways in B cells from irAE and ICI. GSEA plots of IFN-α and IFN-γ response (F), and oxidative phosphorylation (G). ( H ) The volcano plots of the citrullinated or noncitrullinated relative IgG or IgM isotype autoantigen levels comparing RA versus HC, irAE versus ICI, irAE versus HC, or irAE versus RA. The autoantigens were labeled when P < 0.01. TNF-α reactivities resulted from the administration of anti–TNF-α therapy for the treatment of RA. ( I ) Immunoglobulin isotype levels in the plasma were measured by multiplex assay. HC ( n = 22), irAE ( n = 34), RAC ( n = 46), and ICI ( n = 26). ( J ) CXCL13 levels in the plasma were measured by enzyme-linked immunosorbent assay (ELISA). HC ( n = 20), irAE ( n = 34) RAC ( n = 47), and ICI ( n = 23). ( K ) B-cell activating factor (BAFF) levels in the plasma were measured by multiplex assay. HC ( n = 21), irAE ( n = 34), RAC ( n = 47), and ICI ( n = 18). Data in graphs represent mean ± SEM. Significance was tested by one-way ANOVA [(A) to (D) and (I) to (K)] and logistic regression (H). [(A) to (D) and (F) to (K)] ICI, ICI control.

Article Snippet: For CXCL13, IL-21, and CX3CL1 measurements, the following kits were used: Human CXCL13/BLC/BCA-1 Quantikine Enzyme-Linked Immunosorbent Assay (ELISA) (R&D Systems, catalog no. DCX130), Human IL-21 DuoSet ELISA (R&D Systems, catalog no. DY8879-05), and Human CX3CL1/Fractalkine DuoSet ELISA (R&D Systems, DY365); all steps were performed according to the manufacturer’s instructions.

Techniques: Expressing, Phospho-proteomics, Immunopeptidomics, Labeling, Clinical Proteomics, Multiplex Assay, Enzyme-linked Immunosorbent Assay, Control